Akorn-Strides, LLC Announces its First ANDA Approval For Ketorolac Tromethamine Injection USP, 15 mg/mL and 30 mg/mL
Tuesday, July 17, 2007
BUFFALO GROVE, Ill. – Akorn-Strides, LLC today announced its first ANDA approval for Ketorolac Tromethamine Injection USP, 15 mg/mL and 30 mg/mL. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. and Strides Arcolab Limited. The primary mission for the Joint Venture is developing liquid, lyophilized and dry powder fill generic injectable products targeting several therapeutic markets with a major focus on anti-infectives, analgesics and CNS medicines.
|Drug Name(s)||KETOROLAC TROMETHAMINE (Generic Drug)|
|FDA Application No.||(ANDA) 078299|
|Active Ingredient(s)||KETOROLAC TROMETHAMINE|
|Original Approval Date||July 16, 2007|